| Assessment of Chronic Obstructive Pulmonary Disease (COPD) Therapy From the Physicians Perspective Using Tiotropium as an Example (NCT01036763) | Boehringer Ingelheim | 2010-01-01 |
| Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry II (NCT01040793) | Boehringer Ingelheim | 2010-01-01 |
| Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I (NCT01040130) | Boehringer Ingelheim | 2010-01-01 |
| Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD) (NCT01040403) | Boehringer Ingelheim | 2010-01-01 |
| Relative Bioavailability of BI 671800 HEA in Healthy Male Volunteers (NCT02222233) | Boehringer Ingelheim | 2010-01-01 |
| Post-Marketing Surveillance of Micombi Tablets Survey on the Long-term Use (NCT01050062) | Boehringer Ingelheim | 2010-01-01 |
| Bioequivalence of a Linagliptin / Metformin Fixed-dose Combination (FDC) Tablet Compared With Single Linagliptin and Metformin Tablets Administered Together in Healthy Volunteers (NCT02221401) | Boehringer Ingelheim | 2010-01-01 |
| Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 113823 Powder in Bottle (PiB) and Tablet in Healthy Male Volunteers (NCT02259972) | Boehringer Ingelheim | 2010-01-01 |
| Effect of BI 201335 Mediated UGT1A1 (Uridine-diphosphate-glucuronosyltransferases) Inhibition in Healthy Volunteers (NCT02182375) | Boehringer Ingelheim | 2010-01-01 |
| Antihypertensive Medications and the Risk of Sepsis (NCT02248896) | Boehringer Ingelheim | 2010-01-01 |
| Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib. (NCT01024920) | Boehringer Ingelheim | 2009-12-16 |
| Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients (NCT00904371) | Boehringer Ingelheim | 2009-12-01 |
| Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors (NCT01022853) | Boehringer Ingelheim | 2009-12-01 |
| Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer (NCT01023958) | Boehringer Ingelheim | 2009-11-19 |
| LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer (NCT01015118) | Boehringer Ingelheim | 2009-11-17 |
| Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes (NCT01011868) | Boehringer Ingelheim | 2009-11-01 |
| Assessment of the Safety and Efficacy of Pramipexole Extended Release in Patients With Parkinson's Disease in Routine Clinical Practice (NCT01061567) | Boehringer Ingelheim | 2009-11-01 |
| Tolerability and Potential ECG Effects After a Single Oral Dose of Pentoxyverine Citrate in Healthy Male and Female Volunteers (NCT02183649) | Boehringer Ingelheim | 2009-11-01 |
| Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease (NCT01019694) | Boehringer Ingelheim | 2009-11-01 |
| Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 Diabetes (NCT01012037) | Boehringer Ingelheim | 2009-11-01 |
| Safety and Pharmacokinetics of Single Rising Oral Doses of BI 224436 ZW in Healthy Male Volunteers. (NCT02183662) | Boehringer Ingelheim | 2009-11-01 |
| The Use of Pramipexole and Other Dopamine Agonists and the Risks of Heart Failure and Pneumonia (NCT02236741) | Boehringer Ingelheim | 2009-11-01 |
| Serial Lung Function Measurements in Healthy and Mild Asthmatic Adults After Oral Inhalation of Ethanolic Solutions Containing Two Concentrations of the Excipient Butylated Hydroxytoluene (BHT) Administered With the Respimat® B (RMT-B) (NCT02220673) | Boehringer Ingelheim | 2009-11-01 |
| Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (NCT01004003) | Boehringer Ingelheim | 2009-10-22 |
| BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC) (NCT00979576) | Boehringer Ingelheim | 2009-10-16 |
| A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients (NCT00987935) | Boehringer Ingelheim | 2009-10-01 |
| A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR] (NCT01003899) | Boehringer Ingelheim | 2009-10-01 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 653048 BS H3PO4 Capsule Multiple Rising Doses in Healthy Male Volunteers (NCT02217631) | Boehringer Ingelheim | 2009-10-01 |
| Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours. (NCT00998296) | Boehringer Ingelheim | 2009-10-01 |
| Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone (NCT00996658) | Boehringer Ingelheim | 2009-10-01 |
| Study to Evaluate Safety, Tolerability and Pharmacokinetics of Increasing Repeated Oral Doses of Ambroxol Lozenges in Healthy Male Volunteers (NCT02194283) | Boehringer Ingelheim | 2009-10-01 |
| Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib (NCT00993499) | Boehringer Ingelheim | 2009-10-01 |
| Single and Multiple Oral Doses of Dabigatran Etexilate in Healthy Chinese Subjects (NCT02171572) | Boehringer Ingelheim | 2009-10-01 |
| Randomized, Placebo Controlled, Crossover Study in an Environmental Challenge Chamber to Assess Safety & Efficacy of Three Oral Doses of BI 671800 Versus Fluticasone Propionate and Montelukast in Sensitive Seasonal Allergic Rhinitis Patients Out of Season (NCT01007721) | Boehringer Ingelheim | 2009-10-01 |
| Spiriva Observational Study Measuring Saint George's Respiratory Questionnaire (SGRQ) in Routine Medical Practice in Central & Eastern European Region (NCT01006135) | Boehringer Ingelheim | 2009-10-01 |
| Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform (NCT00977431) | Boehringer Ingelheim | 2009-09-17 |
| Pharmacokinetic Properties of Nevirapine Extended Release Tablets When Administered Orally in Healthy Male Volunteers (NCT02194218) | Boehringer Ingelheim | 2009-09-01 |
| Study to Evaluate the Effect of Multiple Doses of Rifampicin on the Multiple-dose Pharmacokinetics of Linagliptin in Healthy Volunteers (NCT02183584) | Boehringer Ingelheim | 2009-09-01 |
| Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3) (NCT00984620) | Boehringer Ingelheim | 2009-09-01 |
| Relative Bioavailability of BI 10773 Administered Twice Daily Compared BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female Volunteers (NCT02782624) | Boehringer Ingelheim | 2009-09-01 |
| Relative Bioavailability of a Single-dose Administration of BIBW 2992 and Multiple-dose Administration of Ritonavir in Healthy Volunteers (NCT02171754) | Boehringer Ingelheim | 2009-09-01 |
| A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice. (NCT00976950) | Boehringer Ingelheim | 2009-09-01 |
| BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation (NCT00949650) | Boehringer Ingelheim | 2009-08-14 |
| Non-interventional Observational Study With Viramune (Nevirapine) and Various Drug Combinations in the Antiretroviral Combination Treatment of HIV-infected Patients Who Have Already Been Treated for Approx. 10 Years With Viramune (NCT00979420) | Boehringer Ingelheim | 2009-08-01 |
| BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumour (NCT00969761) | Boehringer Ingelheim | 2009-08-01 |
| Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer. (NCT00950742) | Boehringer Ingelheim | 2009-08-01 |
| Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes (NCT00954447) | Boehringer Ingelheim | 2009-08-01 |
| Dose Finding Study of BI 6727 (Volasertib) in Patients With Various Solid Cancers (NCT00969553) | Boehringer Ingelheim | 2009-08-01 |
| BI 1744 CL in Patients With Severe Renal Impairment in Comparison to Subjects With Normal Renal Function (NCT02172118) | Boehringer Ingelheim | 2009-08-01 |
| Relative Bioavailability of Two Fixed Dose Combination Tablets of Linagliptin/Pioglitazone Compared With Single Linagliptin and Pioglitazone Tablets Administered Together to Healthy Male and Female Subjects (NCT02183636) | Boehringer Ingelheim | 2009-08-01 |
| Safety and Tolerability of 4 Different Dosage Strengths of BIBW 2992 Tablets to Healthy Male Volunteers (NCT02171767) | Boehringer Ingelheim | 2009-08-01 |
| Relative Bioavailability of BI 10773 and Linagliptin in Healthy Male Volunteers (NCT02172222) | Boehringer Ingelheim | 2009-07-01 |
| Single Dose of BI 1744 CL in Patients With Mild and Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function (NCT02171832) | Boehringer Ingelheim | 2009-07-01 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients (NCT00947349) | Boehringer Ingelheim | 2009-07-01 |
| Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal Impairment (NCT01907113) | Boehringer Ingelheim | 2009-07-01 |
| Dose Proportionality of Different Dose Strengths of Linagliptin Tablets After Oral Administration to Healthy Male and Female Volunteers (NCT02183480) | Boehringer Ingelheim | 2009-07-01 |
| Multiple Doses of BI 207127 NA, BI 201335 NA Followed by the Combination of BI 207127 NA and BI 201335 NA in Healthy Male Volunteers (NCT02182401) | Boehringer Ingelheim | 2009-07-01 |
| Pharmacokinetics of Single and Multiple Oral Doses of BI 1356 in Healthy Chinese Volunteers (NCT02183532) | Boehringer Ingelheim | 2009-07-01 |
| (Hyoscine Butylbromide) for Abdominal Pain Associated With Cramping on Demand Basis (NCT00932737) | Boehringer Ingelheim | 2009-06-09 |
| Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg Bid (NCT00915772) | Boehringer Ingelheim | 2009-06-01 |
| A Phase I Multiple Dose Pharmacokinetic Study of Nevirapine Extended Release (XR) in HIV-1 Infected Children. (NCT00905489) | Boehringer Ingelheim | 2009-06-01 |
| Safety and Tolerability Study of BIBF 1120 as Intravenous Infusion and Absolute Bioavailability of BIBF 1120 as Soft Gelatine Capsule in Healthy Subjects (NCT02182258) | Boehringer Ingelheim | 2009-06-01 |
| Relative Bioavailability of Single Doses of Dabigatran Etexilate When Administered Alone or in Combination With a Single Dose of Ketoconazole or in Combination With q.d. Ketoconazole at Steady State in Healthy Male and Female Volunteers (NCT02170675) | Boehringer Ingelheim | 2009-06-01 |
| Relative Bioavailability of Single Doses of Dabigatran Etexilate in Healthy Volunteers (NCT02173717) | Boehringer Ingelheim | 2009-06-01 |
| Bioavailability of BI 10773 and Pioglitazone in Healthy Male Volunteers (NCT02276365) | Boehringer Ingelheim | 2009-06-01 |
| Study to Investigate Safety With Special Emphasis on ECG Effects and Tolerability After Oral Doses of Dextromethorphan Hydrobromide Monohydrate in Healthy Male and Female Subjects (NCT02191176) | Boehringer Ingelheim | 2009-06-01 |
| Safety and Tolerability of Dabigatran Etexilate in Adolescents (NCT00844415) | Boehringer Ingelheim | 2009-06-01 |
| Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients (NCT00935220) | Boehringer Ingelheim | 2009-06-01 |
| Metabolism and Pharmacokinetics of Oral Solution of [14C]-BI 201335 in Healthy Male Volunteers (NCT02182349) | Boehringer Ingelheim | 2009-06-01 |
| Afatinib and Vinorelbine in Tumours Known to Overexpress EGFR and/or HER2 (NCT00906698) | Boehringer Ingelheim | 2009-06-01 |
| Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension (NCT00926289) | Boehringer Ingelheim | 2009-06-01 |
| Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease (NCT00932646) | Boehringer Ingelheim | 2009-06-01 |
| Actuation Indicator Trial in Patients With COPD (NCT00928746) | Boehringer Ingelheim | 2009-06-01 |
| Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease (NCT00931385) | Boehringer Ingelheim | 2009-06-01 |
| BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer (NCT00904839) | Boehringer Ingelheim | 2009-05-01 |
| Bioavailability Study of Ranitidine Hydrochloride (Maximum Strength ZANTAC 150®) Compared to Two Different 150 mg Ranitidine Hydrochloride Oral Disintegrating Tablet (ODT) in Fasting, Healthy Male Volunteers (NCT02195804) | Boehringer Ingelheim | 2009-05-01 |
| 4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients (NCT00905632) | Boehringer Ingelheim | 2009-05-01 |
| Bioavailability of BI 10773 and Sitagliptin in Healthy Male Volunteers (NCT02172196) | Boehringer Ingelheim | 2009-05-01 |
| PRO-POWER: Hypertension With Risk Factors for a Duration of 24 Weeks With Micardis 80mg/Micardis Plus 80mg/12.5mg (NCT00936208) | Boehringer Ingelheim | 2009-05-01 |
| Telmisartan 80mg+Hydrochlorothiazide (HCTZ) 25 mg in Hypertension: an Observational Study (NCT00909038) | Boehringer Ingelheim | 2009-05-01 |
| Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I in Healthy Volunteers (NCT02182414) | Boehringer Ingelheim | 2009-05-01 |
| Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Mono Products of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers (NCT02222428) | Boehringer Ingelheim | 2009-04-01 |
| Non-interventional Observational Study on the Influence of Pramipexole on Sensory Symptoms of Restless Legs Syndrome (RLS) (NCT00887289) | Boehringer Ingelheim | 2009-04-01 |
| 4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM) (NCT00885118) | Boehringer Ingelheim | 2009-04-01 |
| Relative Bioavailability of BI 10773 and Glimepiride in Healthy Male Volunteers (NCT02172261) | Boehringer Ingelheim | 2009-04-01 |
| Investigating the Effect of Telmisartan (Micardis®) on the Average 24h Blood Pressure of Therapy-naive and Therapy-experienced Patients (NCT00879411) | Boehringer Ingelheim | 2009-04-01 |
| Telmisartan Tab Hypertension (NCT00890084) | Boehringer Ingelheim | 2009-04-01 |
| Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery (NCT00847301) | Boehringer Ingelheim | 2009-04-01 |
| Bioavailability of Combination Tablet BI 1356/Metformin Compared With Single BI 1356 and Metformin Administered Together to Healthy Male and Female Subjects (NCT02173639) | Boehringer Ingelheim | 2009-04-01 |
| Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension (NCT00881530) | Boehringer Ingelheim | 2009-03-01 |
| Safety and Pharmacokinetics of Quinidine Alone and in Combination With Dabigatran Etexilate (NCT02171624) | Boehringer Ingelheim | 2009-03-01 |
| Non-Interventional Observational Study With Viramune Plus Antiretroviral in HIV Infected Patients (NCT00876733) | Boehringer Ingelheim | 2009-03-01 |
| Trial of BI 6727 (Volasertib) Monotherapy and BI 6727 in Combination With Pemetrexed Compared to Pemetrexed Monotherapy in Advanced NSCLC (NCT00824408) | Boehringer Ingelheim | 2009-03-01 |
| Bioavailability of Different Applications of Dabigatran in Healthy Volunteers (NCT02171611) | Boehringer Ingelheim | 2009-03-01 |
| Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours (NCT00875433) | Boehringer Ingelheim | 2009-03-01 |
| MEN STUDY (ESTUDIO MEN) Quality of Life in Patients With BPH and Nocturia Before and After Tamsulosin Ocas® Treatment (NCT00885027) | Boehringer Ingelheim | 2009-03-01 |
| Assess the Efficacy and Tolerability of Antistax Film-coated Tablets in Patients With Chronic Venous Insufficiency (NCT00855179) | Boehringer Ingelheim | 2009-03-01 |
| Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension (NCT00860262) | Boehringer Ingelheim | 2009-03-01 |
| Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Free Combination of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers (NCT02220660) | Boehringer Ingelheim | 2009-03-01 |
| BIBF 1120 + Docetaxel (Japan) in Patients With Advanced Non-small-cell Lung Cancer, Phase I (NCT00876460) | Boehringer Ingelheim | 2009-03-01 |